MedPage Today on MSN
Some Cancers May Be Slightly Elevated in Women Who've Had Fertility Treatment
But overall cancer incidence similar to the general population, Australian study shows ...
Findings indicate small increases in certain cancers linked to assisted reproduction, though overall cancer incidence aligns ...
ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...
Bay Area laboratory solutions company Agilent Technologies has agreed to acquire Biocare Medical, a pathology solutions business, in an all-cash transaction valued at $950 million. | Bay Area ...
A Decision Score provides prognostic discrimination for 10-year locoregional recurrence, with rising score associated with ...
Study fully enrolled ahead of schedule, with 366 of 366 BCG-naïve NMIBC patients randomized to receive BCG alone or ANKTIVA plus BCG Interim analysis requested by the FDA demonstrated a statistically ...
Daiichi Sankyo submits Enhertu sNDA in Japan as adjuvant therapy for patients with HER2 positive early breast cancer: Tokyo Monday, March 2, 2026, 12:00 Hrs [IST] Daiichi Sankyo h ...
Explore how proteomics in cancer research advances tumor profiling, biomarker discovery, and precision oncology workflows.
Oncology Media Relations Oncology_media_relations@its.jnj.com Investor contact: Jess Margevich investor-relations@its.jnj.com ...
Jane Fallon revealed she has been diagnosed with early-stage Breast Cancer after a routine mammogram detected abnormalities despite no symptoms. The longtime partner of Ricky Gervais said the ...
ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results